此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Opiranserin for Minimally Invasive Cholecystectomy

2026年6月16日 更新者：Young Song、Gangnam Severance Hospital

Comparison of Opiranserin/Acetaminophen Versus Ibuprofen/Acetaminophen for Postoperative Pain Management After Minimally Invasive Cholecystectomy: A Randomized, Controlled, Non-inferiority Trial

The purpose of this study is to evaluate whether the combination therapy of opiranserin and acetaminophen is non-inferior to the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen for postoperative pain management after minimally invasive cholecystectomy.

This is a single-center, randomized, controlled, non-inferiority clinical trial in adult patients undergoing minimally invasive cholecystectomy. Participants will be randomly assigned to either the Treatement group (opiranserin + acetaminophen) or the control group (NSAIDs + acetaminophen) in a 1:1 ratio to compare the analgesic efficacy and safety between the two analgesic regimens.

研究概览

地位

招聘中

条件

干预/治疗

研究类型

介入性

注册 (估计的)

88

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

学习地点

  • 韩国
      • Seoul、韩国、06273
        • 招聘中
        • Gangnam Severance Hospital
        • 接触：
      • Seoul、韩国、06273
        • 尚未招聘
        • Gangnam Severance Hospital
        • 接触：
          • Young Song

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Adult patient undergoing minimally invasive cholecystectomy

Exclusion Criteria:

  • Known hypersensitivity or allergy to acetaminophen, NSAIDs, opiranserin, or fentanyl.
  • pre-existing chronic pain,
  • clinically significant ECG findings (QRS > 200 msec, QTcF >450 msec)
  • severe renal impairment
  • severe hepatic impairment

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：四人间

武器和干预

参与者组/臂
干预/治疗
实验性的：Opiranserin+Acetaminophen group
In the Opiranserin+Acetaminophen group, opiranserine 1000mg infusion will be provided over 10 hr. IV Acetaminophen 1g will be provided q 8h until 24 h potperatively.
药品：Opiranserin+Acetaminophen
In the Opiranserin+Acetaminophen group, opiranserine 1000mg infusion will be provided over 10 hr. Opiranserin infusion will be started after the indduction of anesthesia. After laoding dose (160mg ) over 30 minutes, maintenace dose (840mg) will be infused over 9hr 30min. IV Acetaminophen 1g will be provided q 8h until 24 h potperatively.
其他名称：
  • 第一臂
有源比较器：Acetaminophen+NSAIDs group
In the Acetaminophen+NSAIDs group, Normal saline 500 ml will be provided over 10hr. IV Acetaminophen 1g and ibuprofen 300mg will be provided q 8h until 24 h potperatively.
药品：Acetaminophen+NSAIDs
In the Acetaminophen+NSAIDs group, Normal saline 500 ml will be provided over 10hr. IV Acetaminophen 1g and ibuprofen 300mg will be provided q 8h until 24 h potperatively.
其他名称：
  • 第二臂

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Area under the curve of the pain score at rest through 12 hours (NRS·h)
大体时间：Until 12 hours postoperatively
Area under the curve of the numeric rating scale pain score at rest through 12 hours (Numerical Rating Scale·h), Pain score will be assess with the numerical rating scale (NRS), ranging from 0 (0, no pain) to 10 (maximum, worst pain), higher scores indicate greater pain intensity.
Until 12 hours postoperatively

次要结果测量

结果测量
措施说明
大体时间
opioid consumption
大体时间：until 24hours postopratively
until 24hours postopratively
time to first rescue analgesics
大体时间：until 24hours
time to first rescue analgesic requirements
until 24hours
incidence of nausea, vomiting
大体时间：until 24hours
incidence of nausea, vomiting during postoperative 24 hours
until 24hours
hospital length of stay
大体时间：until discharge, about 1-7 days
length of hospitalization
until discharge, about 1-7 days
Area under the curve of the pain score at rest through 24 hours
大体时间：until 24hours postoperatively

Area under the curve of the numeric rating scale pain score at rest through 24 hours.

Area under the curve of the numeric rating scale pain score at rest through 24 hours (Numerical Rating Scale·h), Pain score will be assess with the numerical rating scale (NRS), ranging from 0 (0, no pain) to 10 (maximum, worst pain), higher scores indicate greater pain intensity.
until 24hours postoperatively
pain at rest
大体时间：at 0.5, 2, 4, 6, 12, 18, 24hours postoperatively
numeric rating scale pain score at rest, Pain score will be assess with the numerical rating scale (NRS), ranging from 0 (0, no pain) to 10 (maximum, worst pain), higher scores indicate greater pain intensity.
at 0.5, 2, 4, 6, 12, 18, 24hours postoperatively
pain during movement
大体时间：at 0.5, 2, 4, 6, 12, 18, 24hours postoperatively
numeric rating scale pain score during movement Pain score will be assess with the numerical rating scale (NRS), ranging from 0 (0, no pain) to 10 (maximum, worst pain), higher scores indicate greater pain intensity.
at 0.5, 2, 4, 6, 12, 18, 24hours postoperatively
nausea severity
大体时间：until 24hours
severity of nausea using 0-10 numeric rating scale Nausea severity will be assess with the numerical rating scale (NRS), ranging from 0 (0, no nausea) to 10 (maximum, worst nausea), higher scores indicate greater nausea severity.
until 24hours
patient satisfaction
大体时间：24hours postoperatively
patient satisfaction regarding pain management asked at 24 hours postoperatively, using 0-10 scale Patient satisfaction will be assessd with the numerical rating scale (NRS), ranging from 0 (0, totally unsatisfied) to 10 (maximum, totally satisfied), higher scores indicate greater patient satisfaction.
24hours postoperatively
Quality of Recovery
大体时间：24hours postoperatively
Questionnaire of 15-item Quality of Recovery (QoR-15). Each item is scored on an 11-point numerical rating scale from 0 to 10. Total score range: Minimum 0 to maximum 150. Higher values indicate a better quality of postoperative recovery.
24hours postoperatively

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Gangnam Severance Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月10日

初级完成 (估计的)

2028年5月25日

研究完成 (估计的)

2028年5月30日

研究注册日期

首次提交

2026年5月27日

首先提交符合 QC 标准的

2026年5月27日

首次发布 (实际的)

2026年6月2日

研究记录更新

最后更新发布 (实际的)

2026年6月18日

上次提交的符合 QC 标准的更新

2026年6月16日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • 3-2026-0114

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅